A rare and highly malignant Stewart-Treves syndrome case after breast cancer surgery: a case report

Hongrui Lu¹, Xiaodong Yang¹, Ziguan Zhu¹, Xiuming Zhu², Enqi Guo¹, Rong Yuan³

¹Plastic & Reconstructive Surgery Center, Department of Hand and Reconstructive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China; ²Oncology Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China; ³Nursing Division, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, China

Correspondence to: Rong Yuan. Nursing Division, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou 310014, China. Email: 719196569@qq.com.

Background: Stewart-Treves syndrome (STS) is a lymphatic sarcoma secondary to chronic lymphedema of the extremities. Most STS patients have a history of breast cancer and have undergone radical mastectomy and postoperative radiation and chemotherapy. It usually occurs 11 to 12 years after surgery, and about 0.45% of patients are estimated to have the disease. The characteristics of STS include that it is clinically relatively rare, has a high degree of malignancy, can spread easily in the absence of timely treatment, and has low survival rate. Herein, we report a case of STS which developed 13 years after breast cancer-related lymphoedema (BCRL). It allows doctors to recognize and detect the disease earlier.

Case Description: A 74-year-old woman had undergone modified radical mastectomy 13 years ago for invasive ductal breast cancer in her left breast. After multiple rounds of postoperative chemoradiotherapy, multiple purple lesions were found in the left upper limb during physical examination in April 2021. The lesions spread rapidly and were varied in size. An immediate skin biopsy reported the lesions as STS. The patient was diagnosed with lymphangiosarcoma with metastasis (STS). The surgical method was shoulder joint amputation, chest wall resection, and local flap transfer. After surgery, the patient underwent 6 rounds of paclitaxel 300 mg + carboplatin 300 mg chemotherapy. After chemotherapy, the patient's wound healed and the suspected metastasis disappeared. At the time of writing, she has survived for more than 13 months, and her quality of life has improved significantly, to the satisfaction of the patient and her family. The patient is able to eat normally and lead a normal life with some assistance, without significant weight loss.

Conclusions: Although rare, STS is a serious invasive complication of breast cancer surgery. To increase their relative survival time, patients with BCRL need to identify and thoroughly investigate rapidly progressing skin lesions, and undergo timely surgery.

Keywords: Case report; Stewart-Treves syndrome (STS); lymphedema; lymphangiosarcoma

Submitted May 25, 2022. Accepted for publication Jul 05, 2022.

doi: 10.21037/gs-22-344

View this article at: https://dx.doi.org/10.21037/gs-22-344
A female patient, born on 1 February 1948, with no relevant family history, underwent modified radical mastectomy for infiltrating ductal breast cancer in her left breast in 2008. The postoperative pathology suggested invasive ductal breast cancer with ipsilateral axillary metastasis of 10/31. After surgery, taxotere and adriamycin (TA) regimen chemotherapy was performed for 6 rounds and radiotherapy was performed for 24 times. Swelling of the left upper arm, forearm, back of hand, and finger occurred immediately after surgery, which was diagnosed as upper limb lymphedema. In April 2021, due to the sudden appearance of multiple purple erythema on the left upper limb, which rose higher than the skin surface and was accompanied with pain, the patient presented to the Zhejiang Provincial People’s Hospital for diagnostic resection of local lesions on the left upper limb. The pathological findings of the left upper limb were consistent with lymphedem-associated lymphangiosarcoma. The immunohistochemical staining results were as follows: tumor cells ERG(+), CD34(+), c-myc(+), Ki67(+, 90%), P53(mutant), EMA(−), CK(Pan)(−), Fli-1(−), general photos of the patient are shown in Figure 1.

Physical examination yielded the following findings: the patient’s left upper limb had obvious edema, with multiple irregular purplish-red plaques elevated above the skin surface, some of which were ulcerated and bleeding; the skin was hard and some of the plaques showed leather-like changes. The patient had severe pain and poor upper limb mobility.

On 16 April 2021, the preoperative PET-CT results were as follows: left chest wall soft tissue thickening with increased 18F-fluorodeoxyglucose (FDG) metabolism, which led us to consider the possibility of tumor invasion. Right axillary lymph node metastasis was possible. Multiple thickening of the skin in the subcutaneous fat space of the left upper limb was flocculent, nodular, and cord-like. Patchy, low-density shadow of the muscle bundles were present around the left humerus, ulna, and radius, and increased metabolism of FDG was observed above this area, which was considered consistent with the influencing manifestations of sarcoma. The preoperative pathological results of multiple tissues were consistent, indicating a high degree of malignancy, and multiple metastases were found in the axillary lymph nodes and chest wall skin. Combined with preoperative biopsy, MR and PET-CT, it was determined that the patient had metastases in the left chest wall, neck, and right axilla.

The decision to perform amputation and resection of

Figure 1 Before surgery, there were multiple purple patches on the upper limbs.
the chest wall lesions was made after multidisciplinary preoperative discussion. The malignancy of the tumor was very high, and the 1-year survival rate was reported to be very low. After our multidisciplinary discussion, the patient and her family were made aware of the characteristics of high malignancy and low survival rate of the tumor. The patient accepted our treatment plan of amputation + chemotherapy and signed the informed consent. The patient underwent shoulder amputation, chest wall metastasis resection, and local flap transfer under general anesthesia on 23 April 2021. The operation went smoothly, as shown in Figure 2 and Figure 3. Postoperative skin necrosis still occurred in the chest of the patient (Figure 4).

Tumor markers were in the normal range during treatment. Postoperative pathological photographs are shown in Figure 5. After surgery, the patient received chemotherapy in the oncology department of our hospital, using paclitaxel 300 mg + carboplatin 300 mg chemotherapy for 6 rounds (24 June 2021 to 7 October 2021).

The right axillary lymph nodes were repeatedly inspected during chemotherapy and found to shrink and disappear. A year after surgery, the patient's wound had healed, the previous metastasis disappeared, and her quality of life had improved (Figures 6, 7). To date, the patient has survived
Discussion

The overall prognosis of STS is poor; it is characterized by rapid progression, and is prone to distant metastasis. Its incidence is about 0.07–0.45% of patients who survive more than 5 years after breast cancer surgery (5-7). Therefore, the clinical understanding of STS in the lower limbs is generally insufficient, and it is easily misdiagnosed and missed. Lymphangiosarcoma of the upper extremity is often found in patients with long-term lymphedema after breast cancer surgery. The clinical manifestations are not specific at the early stage, the lesions progress quickly, the prognosis is poor, and it is difficult to distinguish from other skin diseases at the early stage. Doctors have different cognitive levels of hemangiosarcoma, which influences whether early detection and treatment are initiated. The level of medical treatment also affect the prognosis of this disease. Early pathological biopsy is helpful for diagnosis and treatment. Due to the rarity of STS, even relatively experienced physicians may overlook its potential occurrence, and it is recommended that similar signs be detected and eliminated by biopsy as soon as possible. Lymphangitic sarcomas, once found, are more likely to metastasize to the chest wall and the contralateral axilla, and even to the whole body. Recurrence of left axillary metastasis and eventual death have been reported months after amputation of right lymphosarcoma (8). In the case reported here, the potential of STS was recognized in a timely manner, the treatment process of pathologic diagnosis was performed in time, and our diagnosis was timely and accurate. On preoperative PET-CT, we found that the tumor had spread rapidly to the entire upper limb, left chest wall, and contralateral axilla, and we chose shoulder amputation and side breast tissue resection. The advantage of surgery is that the tumor lesions can be removed as much as possible, but the disadvantage is that the trauma is relatively large, and the side chest wall does not heal easily in one stage. After dressing change, the site can be healed. In this case, the suspected metastasis in the right axilla could not be completely removed after evaluation, so the surgery was not complete and the second stage chemotherapy was needed. However, the choice of surgery was correct, and the patient and her family agreed with our treatment plan. Fortunately, the patient was very sensitive to our chemotherapy regimen, the chemotherapy effect was good, the metastasis decreased and disappeared,
and the chest wall wound healed. She has survived for more than 13 months with improved quality of life through active management after chemotherapy. The patient is able to eat normally and lead a normal life with some assistance, without significant weight loss. The patient and her family are very satisfied with our treatment.

The confirmation of STS is mainly via physical examination and pathology, and can be assisted by Doppler ultrasound, MR and PET-CT. Laboratory indicators including tumor indicators are not remarkable for this case. Surgical treatment as soon as possible after diagnosis combined with postoperative chemotherapy, immunotherapy, and targeted therapy can improve patient survival, among which targeted therapy may be the development direction of future treatment for cutaneous angiosarcoma. Aggressive treatment of BCRL may be a good way to prevent STS.

Acknowledgments

Funding: The study was supported by the Medical and Health Science and Technology Project of Zhejiang Province (Nos. 2019KY297 and 2021KY516).

Footnote

Reporting Checklist: The authors have completed the CARE reporting checklist. Available at https://gs.amegroups.com/article/view/10.21037/gs-22-344/rc

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-22-344/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). This report has been approved by the Ethics Committee of Zhejiang Provincial People’s Hospital (approval No. QT2022191) with the informed consent of the patients and their families. A copy of the written consent is available for review by the editorial office of this journal.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1948;1:64-81.
2. Sharma A, Schwartz RA. Stewart-Treves syndrome: pathogenesis and management. J Am Acad Dermatol 2012;67:1342-8.
3. Leite LL, Rossato V. Stewart-Treves Syndrome as a Rare and Fatal Complication of Post-Traumatic Lymphedema on the Lower Extremity. Dermatol Pract Concept 2021;11:e2021004.
4. Agrawal I, Ray A, Kar BR, et al. Stewart-Treves Syndrome
5. Cui L, Zhang J, Zhang X, et al. Angiosarcoma (Stewart-Treves syndrome) in postmastectomy patients: report of 10 cases and review of literature. Int J Clin Exp Pathol 2015;8:11108-15.

6. Taşdemir A, Karaman H, Ünal D, et al. Stewart-Treves Syndrome after Bilateral Mastectomy and Radiotherapy for Breast Carcinoma: Case Report. J Breast Health 2015;11:92-4.

7. Alan S, Aktas H, Ersoy ÖF, et al. Stewart Treves Syndrome in a Woman with Mastectomy. J Clin Diagn Res 2016;10:WD01-2.

8. Borman P, Yaman A, Gököz Ö. Stewart-Treves Syndrome: A Rare But Aggressive Complication of Breast Cancer-Related Lymphedema. Eur J Breast Health 2021;17:378-82.

Cite this article as: Lu H, Yang X, Zhu Z, Zhu X, Guo E, Yuan R. A rare and highly malignant Stewart-Treves syndrome case after breast cancer surgery: a case report. Gland Surg 2022;11(7):1264-1269. doi: 10.21037/gs-22-344